Recently, Coniscient Robotics, a developer specializing in surgical robots, declared the successful closure of an oversubscribed financing round, raising approximately US$200 million. The investor lineup included prominent entities such as Hong Kong Investment Corporation Limited, alongside continued support from existing investors like Gaorong Capital.

The funds garnered in this round are earmarked for expediting commercialization initiatives on both domestic and international fronts. Additionally, they will fuel the progression and clinical registration of the company's next-generation products.

Established in September 2019, Coniscient Robotics has made significant strides with its flagship product, the Sentire® laparoscopic surgical robot. This innovative robot has not only secured regulatory clearance but has also been clinically deployed, marking a milestone in achieving complete independent development across the entire supply chain and surmounting supply chain constraints.

In a groundbreaking achievement in August 2025, Coniscient Robotics, in partnership with a research team from the Chinese University of Hong Kong, unveiled the world's inaugural multifunctional automated embodied intelligent platform tailored for surgical robots. This collaboration culminated in the successful execution of the world's first autonomous surgical verification within a clinical environment.

Founder Ou Guowei emphasized the company's unwavering commitment to propelling the commercialization of technological innovations. He also underscored the intention to deepen the globalization strategy, with the ultimate goal of extending the benefits of these advancements to a broader patient base worldwide.